問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL

Division of Neurology

更新時間：2026-06-01

黃瀚可
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃瀚可

List

4Cases

2025-10-15 - 2032-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

  • Condition/Disease

    Parkinson's Disease

  • Test Drug

    Injectable

Participate Sites
6Sites

Recruiting6Sites

2025-12-01 - 2028-06-30

Phase III

Active
TENACITY – A phase III, prospective, randomized, open-label, blinded Probe-Based Evaluation (PROBE) trial evaluating the efficacy and safety of intravenous tenecteplase compared to standard of care in patients with acute ischemic stroke (including sleep-wake stroke) who have been in contact with the patient for more than 4.5 hours since their last known normality and have salvageable ischemic tissue imaging evidence.

  • Condition/Disease

    Acute ischemic stroke (including sleep-wake stroke)

  • Test Drug

    Tenecteplase

Participate Sites
9Sites

Recruiting3Sites

2026-09-01 - 2028-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2026-05-01 - 2030-08-14

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB